[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357735-105":59,"doc-detail-357735-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","capmatinib-for-high-level-met-amplified-metastatic-gastric-cancer-a-case-report-and-literature-review","Capmatinib for High-Level MET-Amplified Metastatic Gastric Cancer - A Case Report and Literature Review","","High-level MET gene amplification is a rare but potentially actionable alteration in gastric cancer, and prior MET-targeted phase III trials did not prospectively select patients with high-level amplification. No MET-directed therapy is established for this subgroup. A 74-year-old woman with heavily pretreated metastatic gastric adenocarcinoma received capmatinib via the BELIEVE trial after comprehensive genomic profiling identified high-level MET amplification (copy number 21).",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/capmatinib-for-high-level-met-amplified-metastatic-gastric-cancer-a-case-report-and-literature-review/357735/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/capmatinib-for-high-level-met-amplified-metastatic-gastric-cancer-a-case-report-and-literature-review/357735.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What molecular alteration was identified in this gastric cancer case?","Question",{"text":113,"@type":114},"Comprehensive genomic profiling identified high-level MET gene amplification with a copy number of 21.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was capmatinib delivered to the patient and what response was observed?",{"text":118,"@type":114},"After expert panel review, the patient received capmatinib through the BELIEVE trial and achieved a confirmed partial response at 8 weeks with a 43.7% reduction in target lesion diameters.",{"name":120,"@type":111,"acceptedAnswer":121},"What was the overall disease course after treatment?",{"text":122,"@type":114},"The response was maintained at 16 weeks, followed by disease progression at 24 weeks, with progression-free survival of approximately 5.5 months.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},357735,1790528338,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Journal of Gastrointestinal Cancer (2026) 57:180  \n[https://doi.org/10.1007/s12029-026-01561-4](https://doi.org/10.1007/s12029-026-01561-4)  \nCASE REPORT  \nCapmatinib for High-Level MET-Amplified Metastatic Gastric Cancer Identified by Comprehensive Genomic Profiling: A Case Report and Literature Review  \nYasuyoshi Sato1,2 · Kousuke Watanabe3 · Mana Matsuoka4 · Yurina Yamada4 · Koichi Yagi2 · Kuniko Sunami5 · Miho Ogawa3 · Katsutoshi Oda3 · Yoshifumi Baba2  \nReceived: 28 June 2026 / Accepted: 3 August 2026 © The Author(s) 2026  \nAbstract  \nHigh-level MET gene amplification is a rare but potentially actionable alteration in gastric cancer. Previous phase III trials of MET-targeted therapies enrolled broadly MET-positive populations without prospective selection for high-level MET amplification, and no MET-directed therapy is currently established for this disease. Here, we report a 74-year-old woman with heavily pretreated metastatic gastric adenocarcinoma harboring high-level MET amplification (copy number 21) identified by comprehensive genomic profiling. Following expert panel review, the patient received capmatinib through the BELIEVE trial (NCCH1901; jRCTs031190104) and achieved a confirmed partial response at 8 weeks, with a 43.7% reduction in the sum of target lesion diameters. The response was maintained at 16 weeks; disease progression was observed at 24 weeks, with a progression-free survival of approximately 5.5 months. In the context of a literature review of MET-targeted therapies in gastric cancer, this case supports further investigation of selective MET inhibition in gastric cancer with high-level MET amplification, a rare molecular subset not prospectively enriched in previous clinical trials.  \nKeywords Gastric cancer · MET amplification · Capmatinib · Comprehensive genomic profiling · Precision oncology · MET-targeted therapy  \nIntroduction  \nGastric cancer remains a leading cause of cancer-related mortality worldwide. Treatment options for patients refractory to standard chemotherapy and immune checkpoint  \n Yasuyoshi Sato [yasuyoshi_s@hotmail.com](yasuyoshi_s@hotmail.com)  \n1 Department of Clinical Oncology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan  \n2 Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan  \n3 Department of Clinical Genomics, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan  \n4 Department of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Sumida-ku, Tokyo, Japan  \n5 Department of Laboratory Medicine, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan  \ninhibitors remain limited. Advances in comprehensive genomic profiling have enabled the identification of rare but potentially actionable molecular alterations in these tumors, facilitating access to matched targeted therapies through precision oncology trials. The clinical relevance of MET gene alterations in gastric cancer, however, remains incompletely defined.  \nAlthough MET protein overexpression is relatively common, true MET gene amplification, particularly at a high copy number, is rare and has been reported in only a small subset of gastric cancers [1] . Several phase III trials evaluating MET-targeted therapies in combination with standard chemotherapy in gastric cancer have failed to demonstrate clinical benefit [2, 3], and no MET-directed therapy is currently recommended for this disease [4] . These trials, however, did not prospectively enrich for patients with high-level MET amplification, which may represent a biologically distinct, MET-dependent molecular subset. Previous reviews have emphasized the importance of biomarker-based strategies for MET-targeted therapy in gastric cancer [5, 6] .  \nCapmatinib is a highly selective MET tyrosine kinase inhibitor with established clinical activity against malignancies driven by MET alterations [7], including non-small cell lung cancer (NSCLC) [8]. However, evidence ","cbCaikMxwrGz5yZr","https://ap.wps.com/l/cbCaikMxwrGz5yZr","pdf",922424,"English","# Abstract\n# Introduction\n# Case Report","[{\"question\":\"What molecular alteration was identified in this gastric cancer case?\",\"answer\":\"Comprehensive genomic profiling identified high-level MET gene amplification with a copy number of 21.\"},{\"question\":\"How was capmatinib delivered to the patient and what response was observed?\",\"answer\":\"After expert panel review, the patient received capmatinib through the BELIEVE trial and achieved a confirmed partial response at 8 weeks with a 43.7% reduction in target lesion diameters.\"},{\"question\":\"What was the overall disease course after treatment?\",\"answer\":\"The response was maintained at 16 weeks, followed by disease progression at 24 weeks, with progression-free survival of approximately 5.5 months.\"}]","Capmatinib for High-Level MET-Amplified Metastatic Gastric Cancer - A Case Report and Literature Review | PDF",1790131594,15]